biostudies-literatureUnknown1(9)Moe S<h4>Background</h4>Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.<h4>Methods</h4>A retrospective study was conducted using extensive programmatic data from 2019 to 2023 in Uzbekistan. We assessed second-line drug-resistant TB (SLDR-TB) rates using phenotypic drug susceptibility testing (pDST). Demographic and clinical characteristics associated with SLDR-TB were analysed using multivariable logistic regression models based on the Allen-Cady approach.<h4>Results</h4IJTLD open391-397https://www.ebi.ac.uk/biostudies/studies/S-EPMC11409172biostudies-literatureSecond-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan.PMC11409172Sinha ASitali NMoe SMikhail ARekart MLGomez DOluya MKalmuratov BParpieva NBidwell GAllamuratova STigay ZSafaev KAzamat IMamitova KKhristusev AGomez-Restrepo CfalseSecond-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan.<h4>Background</h4>Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.<h4>Methods</h4>A retrospective study was conducted using extensive programmatic data from 2019 to 2023 in Uzbekistan. We assessed second-line drug-resistant TB (SLDR-TB) rates using phenotypic drug susceptibility testing (pDST). Demographic and clinical characteristics associated with SLDR-TB were analysed using multivariable logistic regression models based on the Allen-Cady approach.<h4>Results</h42024-01-01T00:00:00Z2024 Sep2026-06-16T03:13:03.941Z2025-04-06T03:42:24.133ZS-EPMC114091723930113310.5588/ijtldopen.24.0351